In a study published in the journal Immunology, Southampton University researchers have shown that a new antibody that they have engineered is able to combine two different anticancer approaches: depleting regulatory T cells and activating killer T cells [1].
Abstract
The costimulatory receptor 4-1BB is expressed on activated immune cells, including activated T cells. Antibodies targeting 4-1BB enhance the proliferation and survival of antigen-stimulated T cells in vitro and promote CD8 T cell-dependent anti-tumor immunity in pre-clinical cancer models. We found that T regulatory (Treg) cells infiltrating human or murine tumors expressed high amounts of 4-1BB. Intra-tumoral Treg cells were preferentially depleted by anti-4-1BB mAbs in vivo. Anti-4-1BB mAbs also promoted effector T cell agonism to promote tumor rejection. These distinct mechanisms were competitive and dependent on antibody isotype and FcgR availability. Administration of anti-4-1BB IgG2a, which preferentially depletes Treg cells, followed by either agonistic anti-4-1BB IgG1 or anti-PD-1 mAb augmented anti-tumor responses in multiple solid tumor models.
Following recent trends in state-of-the-art developments, from cryptocurrencies and universal basic income to biohacking and the surveillance state, transhumanism has been moved into the limelight of political discourse to reshape humanity’s future.
Andrew Vladimirov, Information security specialist, biohacker and one of the original members of the Transhumanist Party UK, spoke in-depth with Sputnik about the rise of transhumanism and its implications.
From bionic eyes to gene editing, how can we use science to bring back sight?
LEXINGTON, Ky. (NOVEMBER 15, 2018) – Space Tango, a leader in the commercialization of space through R&D, bioengineering and manufacturing in microgravity, today announced ST-42, a fully autonomous robotic orbital platform designed specifically for scalable manufacturing in space. Launching in the mid 2020’s, ST-42 aims to harness the unique environment of microgravity to produce high value products across industries; from patient therapeutics to advanced technology products that have the potential to revolutionize industries here on Earth. ST-42 is an extension of the International Space Station’s (ISS) capabilities, and NASA’s creation of a robust commercial marketplace in low Earth orbit (LEO).
ST-42 will bring the economics of production in orbit into reality coupling autonomy with the reduced cost and larger number of launch vehicle providers. Space Tango expects the platform to be at the forefront of new breakthroughs in knowledge discovery, therapeutic solutions and manufacturing, and to provide the required capabilities for creation of new biomedical and technology product sectors in the commercial Space economy.
Rutgers scientists have created a tiny, biodegradable scaffold to transplant stem cells and deliver drugs, which may help treat Alzheimer’s and Parkinson’s diseases, aging brain degeneration, spinal cord injuries and traumatic brain injuries.
Stem cell transplantation, which shows promise as a treatment for central nervous system diseases, has been hampered by low cell survival rates, incomplete differentiation of cells and limited growth of neural connections.
So, Rutgers scientists designed bio-scaffolds that mimic natural tissue and got good results in test tubes and mice, according to a study in Nature Communications. These nano-size scaffolds hold promise for advanced stem cell transplantation and neural tissue engineering. Stem cell therapy leads to stem cells becoming neurons and can restore neural circuits.